PCVX Vaxcyte Inc

$47.67

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Vaxcyte (PCVX) stands at a pivotal moment as it approaches its earnings announcement on November 10, 2025, with both the EPS and revenue estimates set at $0.00, aligning with the whisper number. This alignment suggests that the market is not anticipating immediate financial gains but is instead focused on the company's long-term strategic initiatives and potential breakthroughs in vaccine development. With a market cap of approximately $5.65 billion, Vaxcyte's valuation reflects investor confidence in its innovative pipeline, despite the absence of recent financial results or news. As the company continues to navigate the complexities of the biotech landscape, stakeholders will be keenly observing any updates on its clinical trials and partnerships, which could significantly impact future earnings potential.

Updated On 11/21/2025

About Vaxcyte Inc

Vaxcyte, Inc., a pre-clinical biotech vaccine company, develops novel vaccines to prevent or treat infectious diseases globally. The company is headquartered in Foster City, California.

Website: https://vaxcyte.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1649094
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA, US
Valuation
Market Cap
$3.95B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
1.19
Performance
EPS
$-3.80
Dividend Yield
—
Profit Margin
0.00%
ROE
-20.40%
Technicals
50D MA
$64.15
200D MA
$86.23
52W High
$121.06
52W Low
$27.66
Fundamentals
Shares Outstanding
129M
Target Price
$132.00
Beta
1.26

PCVX EPS Estimates vs Actual

● Estimated
● Actual

PCVX News & Sentiment

Sep 30, 2025 • Benzinga SOMEWHAT-BULLISH
Thermo Fisher Launches Four-Part Bond Offering Ahead Of Possible Government Shutdown - Thermo Fisher Scientific ( NYSE:TMO )
Thermo Fisher Scientific Inc. ( NYSE:TMO ) is tapping the U.S. investment-grade bond market with a four-part, dollar-denominated offering, as companies move to secure funding ahead of a potential U.S. government shutdown.
Sep 11, 2025 • Benzinga NEUTRAL
Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data - Merck & Co ( NYSE:MRK )
Capvaxive triggered immune responses for all 21 strains 30 days after vaccination. Capvaxive outperformed PPSV23 in 9 unique strains and matched it in 12 others. Get the data-driven signals to profit from September volatility ( for free ) → Merck & Co. Inc.
Sep 03, 2025 • GlobeNewswire NEUTRAL
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
VAX-31 Optimized Dose, with Majority of Serotypes Dosed at 4.4mcg and Balance at 3.3mcg, is Designed to Elicit Even Stronger Immune Responses in Infant Population to Protect Against Invasive Pneumococcal Disease ...
Aug 07, 2025 • Benzinga NEUTRAL
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - ADMA Biologics ( NASDAQ:ADMA ) , Airbnb ( NASDAQ:ABNB )
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Thursday. Shares of Redwire Corporation RDW fell sharply in pre-market trading after the company reported worse-than-expected second-quarter financial results and cut its FY25 sales guidance.
Aug 07, 2025 • Motley Fool SOMEWHAT-BULLISH
Vaxcyte ( PCVX ) Q2 Loss Widens 11%
Vaxcyte ( NASDAQ:PCVX ) , a biotechnology company specializing in next-generation vaccines, reported its second quarter 2025 results on August 6, 2025. The company reported a GAAP net loss per share of $ ( 1.22 ) , missing the consensus estimate of $ ( 1.16 ) .
May 01, 2025 • Benzinga SOMEWHAT-BULLISH
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors - Vaxcyte ( NASDAQ:PCVX )
SAN CARLOS, Calif., May 01, 2025 ( GLOBE NEWSWIRE ) -- Vaxcyte, Inc.
Sentiment Snapshot

Average Sentiment Score:

0.127
50 articles with scored sentiment

Overall Sentiment:

Neutral

PCVX Reported Earnings

Aug 06, 2025
Jun 30, 2025 (Pre market)
-0.05 Surprise
  • Reported EPS: $-1.22
  • Estimate: $-1.17
  • Whisper: —
  • Surprise %: -4.3%
May 07, 2025
Mar 31, 2025 (Post market)
-0.07 Surprise
  • Reported EPS: $-1.04
  • Estimate: $-0.97
  • Whisper: —
  • Surprise %: -6.7%
Feb 25, 2025
Dec 31, 2024 (Post market)
-0.03 Surprise
  • Reported EPS: $-1.02
  • Estimate: $-0.99
  • Whisper: —
  • Surprise %: -2.6%
Nov 05, 2024
Sep 30, 2024 (Pre market)
0.3 Surprise
  • Reported EPS: $-0.83
  • Estimate: $-1.13
  • Whisper: —
  • Surprise %: 26.6%
Aug 06, 2024
Jun 30, 2024 (Post market)
-0.12 Surprise
  • Reported EPS: $-1.10
  • Estimate: $-0.98
  • Whisper: —
  • Surprise %: -12.2%
May 08, 2024
Mar 31, 2024 (Post market)
0.32 Surprise
  • Reported EPS: $-0.85
  • Estimate: $-1.17
  • Whisper: —
  • Surprise %: 27.4%
Feb 27, 2024
Dec 31, 2023 (Post market)
-0.75 Surprise
  • Reported EPS: $-1.82
  • Estimate: $-1.07
  • Whisper: —
  • Surprise %: -70.1%
Nov 06, 2023
Sep 30, 2023 (Post market)
-0.07 Surprise
  • Reported EPS: $-0.91
  • Estimate: $-0.84
  • Whisper: —
  • Surprise %: -8.3%
Aug 08, 2023
Jun 30, 2023 (Post market)
0.04 Surprise
  • Reported EPS: $-0.70
  • Estimate: $-0.74
  • Whisper: —
  • Surprise %: 5.4%

Financials